San Francisco, CA, United States
San Francisco, CA, United States

Time filter

Source Type

Patent
Elan Pharmaceuticals Inc. and Foundation University | Date: 2014-05-14

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.


Patent
Foundation University and Elan Pharmaceuticals Inc. | Date: 2013-12-06

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.


Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.


Patent
Elan Pharmaceuticals Inc. | Date: 2013-03-15

Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimers disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.


Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohns Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.


Patent
Elan Pharmaceuticals Inc. | Date: 2013-04-17

The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R^(1), R^(2), R^(3), R^(4), R^(5 )and R^(6), are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinsons disease.


Patent
Biogen Idec and Elan Pharmaceuticals Inc. | Date: 2013-10-02

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).


Compounds are provided having a structure according to Formula (I): wherein A_(1), A_(2), A_(3), Y, R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), m, n and p are defined herein. Further provided are pharmaceutical compositions including the compounds provided and methods of making and using the compounds and compositions as provided, e.g., in the treatment and prevention of various disorders, such as Alzheimers disease.


Patent
Elan Pharmaceuticals Inc. | Date: 2015-01-14

The present invention provides compounds having a structure according to Formula (I): or a salt or solvate thereof, wherein ring A, X, R^(1), R^(2), R^(3), R^(4), R^(5 )and R^(6), are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinsons disease.


Patent
Elan Pharmaceuticals Inc. | Date: 2014-03-12

The present invention provides compounds having a structure according to Formula I. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinsons disease.

Loading Elan Pharmaceuticals Inc. collaborators
Loading Elan Pharmaceuticals Inc. collaborators